Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Post-Relapse Survival Poor in DLBCL After Transplant
Key clinical point: Post-relapse survival following autologous hematopoietic cell transplantation (auto-HCT) in patients with diffuse large B-cell lymphoma (DLBCL) is poor, but timing of relapse may predict outcomes.
Major finding: Median post-relapse overall survival of all DLBCL patients relapsing following auto-HCT was 9.8 months (95% CI, 7-15 months). Patients who relapsed within a year of auto-HCT had a median post-relapse survival of 5.9 months, compared with 56.4 months for later relapse (P less than .0001).
Study details: A retrospective analysis of 228 patients with DLBCL who relapsed after auto-HCT. Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.
Epperla N et al. Blood Adv. 2019 Jun 11; 3(11):1661-9. doi: 10.1182/bloodadvances.2019000102.